No quarterly revenue total was found in TRANSLATIONAL DEVELOPMENT ACQUISITION CORP.'s SEC filings.
Translational Development Acquisition Corp. (TDAC) files with the SEC under industry code 6770, Blank Checks.
Revenue
—
Net income
$946,982
-41.7% vs year-ago quarter
Operating cash flow
$-338,753
-97.7% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
0
Net cash
—
Operating margin
—
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- TDAC (Nasdaq), TDACU (Nasdaq), TDACW (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1926599
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$661,050 | -$281,161 | -$162,345 | -$213,658 | -$221,127 |
| Net income | $946,982 | $1.3M | $1.6M | $1.7M | $1.6M |
| Operating cash flow | -$338,753 | -$305,157 | -$117,363 | -$88,105 | -$171,345 |
| Total assets | $157.4M | $183.3M | $181.7M | $180.0M | $178.2M |
| Total liabilities | $7.8M | $6.9M | $6.6M | $6.5M | $6.3M |
| Stockholders' equity | -$7.7M | -$6.8M | -$6.5M | -$6.4M | -$6.2M |
| Cash and investments | $85,877 | $24,630 | $29,787 | $47,150 | $35,255 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 27, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Other events
|
Jul 8, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Other events
|
Jun 23, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Material agreement, Bylaw or fiscal year change, Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Jun 12, 2026 | Jun 12, 2026 |
All 80 Translational Development Acquisition Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.